Quality of life

Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU

Retrieved on: 
Thursday, August 18, 2022 - 10:00am

signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.

Key Points: 
  • signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.
  • Malaysian Genomics is the first company in Malaysia to pioneer genomics and genetic screening in Malaysia for over 17 years.
  • MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare.
  • Encik Azri Azerai, Executive Directorof Malaysian Genomics said, "We look forward to sharing our experience in genomics, bioinformatics, and biopharmaceuticals with MAHSA Health via this collaboration.

Humana Board Declares Payment of Quarterly Dividend to Stockholders

Retrieved on: 
Thursday, August 18, 2022 - 11:30am

Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.7875 per share payable on October 28, 2022 to stockholders of record as of the close of business on September 30, 2022.

Key Points: 
  • Humana Inc. (NYSE: HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.7875 per share payable on October 28, 2022 to stockholders of record as of the close of business on September 30, 2022.
  • Humana Inc. (NYSE: HUM) is committed to helping our millions of medical and specialty members achieve their best health.
  • Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large.
  • More information regarding Humana is available to investors via the Investor Relations page of the companys website at humana.com , including copies of:

Korea Western Power Company, Tallgrass, and PSM to Collaborate on Utility Scale Decarbonization

Retrieved on: 
Thursday, August 18, 2022 - 12:00pm

Se-moon Lee, Head of New Overseas Business Department from KOWEPO, said, We are delighted to cooperate with Tallgrass and PSM, which have expertise in clean hydrogen co-fired power generation projects.

Key Points: 
  • Se-moon Lee, Head of New Overseas Business Department from KOWEPO, said, We are delighted to cooperate with Tallgrass and PSM, which have expertise in clean hydrogen co-fired power generation projects.
  • KOWEPO is developing a hydrogen co-firing project in The Netherlands and a green ammonia production project in UAE.
  • By partnering with Tallgrass and PSM, we have a new opportunity to enter the US power industry and will help expand the foundation to meet future decarbonized energy needs in the US.
  • We are pleased to work with KOWEPO and PSM on another important step to spur investment in decarbonizing U.S. power generation through clean hydrogen, said Blake Hotzel, Tallgrass Vice President of Business Development.

InvestmentPitch Media Video Discusses LOVE Pharma’s Definitive Agreement to Acquire Doc Hygiene Pharmaceuticals Inc.

Retrieved on: 
Thursday, August 18, 2022 - 11:00am

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Key Points: 
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company.
  • Designed and developed in the United States, DOC HYGIENE provides a mess-free, compact alternative to traditional, bulky, bottled hand sanitizer.
  • With premium, germ-killing capability, DOC HYGIENEs single-use hand sanitizing packets meet FDA standards and exceed the recommended CDC guidelines for healthy hygiene.
  • Love Pharma has paid a fee not exceeding $2,000 in cash to have its current news release produced in video format.

ITM Acquires a New Platform for the Development of Next-Generation Theranostics

Retrieved on: 
Thursday, August 18, 2022 - 10:18am

By extending our diagnostic and therapeutic portfolio, ITM consequently pursues the theranostic concept of molecular precision oncology.

Key Points: 
  • By extending our diagnostic and therapeutic portfolio, ITM consequently pursues the theranostic concept of molecular precision oncology.
  • The acquisition gives ITM access to a DATA chelator-based platform technology leveraging gallium-68 (68Ga) as the fastest growing PET radionuclide to develop new targeted PET solutions.
  • ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors.
  • We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply.

Fraser Institute News Release: Hundreds of studies find economic freedom works

Retrieved on: 
Thursday, August 18, 2022 - 10:00am

TORONTO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- According to a wide-ranging literature review, economic freedom helps produce faster economic growth, higher living standards and more happiness.

Key Points: 
  • TORONTO, Aug. 18, 2022 (GLOBE NEWSWIRE) -- According to a wide-ranging literature review, economic freedom helps produce faster economic growth, higher living standards and more happiness.
  • More than 50 per cent of the papers reported good correlations between economic freedom (as measured by the index) and good outcomes (faster economic growth, higher living standards, reduced conflict, etc.)
  • The research shows that economic freedom boosts prosperity and economic growth and also leads to positive outcomes in others areas, said Lawson.
  • The majority of studies in the following areas found economic freedom was related to:
    Personal choice, voluntary exchange and open markets remain the cornerstones of economic freedom, which is key to prosperity worldwide, Lawson said.

Fraser Institute News Release: Share of total spending on child benefits for families with incomes less than $60,000 fell from 42.9% to 29.7%

Retrieved on: 
Thursday, August 18, 2022 - 10:00am

While the federal government often claims that child benefits go to Canadian families who need the money the most, the shift in overall spending tells a different story, said Jason Clemens, executive vice-president of the Fraser Institute and co-author of Adjusting for the Canada Child Benefits Tax-Free Status .

Key Points: 
  • While the federal government often claims that child benefits go to Canadian families who need the money the most, the shift in overall spending tells a different story, said Jason Clemens, executive vice-president of the Fraser Institute and co-author of Adjusting for the Canada Child Benefits Tax-Free Status .
  • In 2016, the federal government replaced two child-benefit programs with the Canada Child Benefit (CCB), which provides tax-free benefits to eligible families with children under the age of 18.
  • At the same time, the share of total child-benefit spending on families with incomes between $60,000 and $180,000 increased from 49.2 per cent to 66.8 per cent.
  • While the share of total child-benefit spending on families with incomes above $180,000 declined from 7.9 per cent to 3.5 per cent.

A Success Story for the Kozyavkin Program for Cerebral Palsy at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Thursday, August 18, 2022 - 6:00am

She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.

Key Points: 
  • She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.
  • Abu Dhabi & Al Ain branches of Cambridge Medical and Rehabilitation Center (CMRC) provide the Intensive Neuro Rehabilitation System (INRS), known as The Kozyavkin Method.
  • The world-class rehabilitation program was created by Dr. Vladimir Kozyavkin over 30 years ago and is accredited by the European Medical Association (EMA.)
  • Dr. Howard Podolsky, Group Chief Executive officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Najat.

A Success Story for the Kozyavkin Program for Cerebral Palsy at Cambridge Medical & Rehabilitation Center

Retrieved on: 
Thursday, August 18, 2022 - 6:00am

She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.

Key Points: 
  • She has undergone four cycles of the program and regular Physiotherapy, Occupational Therapy, and Speech and Language Pathology sessions with great success.
  • Abu Dhabi & Al Ain branches of Cambridge Medical and Rehabilitation Center (CMRC) provide the Intensive Neuro Rehabilitation System (INRS), known as The Kozyavkin Method.
  • The world-class rehabilitation program was created by Dr. Vladimir Kozyavkin over 30 years ago and is accredited by the European Medical Association (EMA.)
  • Dr. Howard Podolsky, Group Chief Executive officer, commented, "Cambridge Medical and Rehabilitation Center is humbled and privileged to provide innovative and ground-breaking care to patients such as Najat.

Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)

Retrieved on: 
Thursday, August 18, 2022 - 6:00am

We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.

Key Points: 
  • We very much welcome NICEs decision, which means that eligible patients and clinicians have another choice of treatment for this debilitating condition.
  • NICEs decision represents a major advancement for the treatment of GPA/MPA in the UK, said Prof. David Jayne, Professor of Clinical Autoimmunity, University of Cambridge.
  • Patients will now have access to a new therapy option that could help them optimize their treatment outcomes.
  • Tavneos was developed by ChemoCentryx, Inc., who is also developing Tavneos for the treatment of patients with C3 Glomerulopathy (C3G) and hidradenitis suppurativa (HS).